Products with Pro-apoptotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5241 | Medicarpin |
| 1. Medicarpin, a legume phytoalexin, acts as an estrogen receptor (ER) agonist, can stimulate osteoblast differentiation likely via ERβ, promote achievement of peak bone mass, and is devoid of uterine estrogenicity; in addition, given its excellent oral bioavailability, it can be potential osteogenic agent. 2. Medicarpin exhibits no uterine estrogenicity, however it can inhibit osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. 3. Medicarpin and maackiain and two of their biosynthetic precursors inhibit the constitutive and phenobarbital (PB)-induced types of AHH, but have little effect on the 3-methylcholanthrene (MC)-induced type of AHH. 4. Medicarpin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. 5. Medicarpin has antifungal activity. | |
| BCN5258 | Myricanol |
| 1. Myricanol can elicit growth inhibitory and cytotoxic effects on lung cancer cells. 2. Myricanol can significantly decelerate tumor growth in vivo by inducing apoptosis. | |
| BCN5280 | Nortrachelogenin |
| 1. (+)-Nortrachelogenin shows effects on the central nervous system producing depression in rabbits. 2. (-)-Nortrachelogenin can induce membrane disruption and caspase-dependent apoptosis. 3. Nortrachelogenin shows anti-plasmodium activity of 14.50 dg/ml. 4. Nortrachelogenin has anti-inflammatory properties. 5. Nortrachelogenin is a novel agent for prostate cancer therapy with ability to inhibit Akt membrane localization and activity as well as the activation of growth factor receptors, thereby efficiently synergizing with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), exposure. 6. (-)-Nortrachelogenin exerts its antibacterial effect by disorganizing and perturbing the cytoplasmic membrane. 7. (+)-Nortrachelogenin is moderately active against HIV-1 in vitro. 8. Nortrachelogenin shows moderate inhibiting activities on NF- κB signaling pathway induced by TNFα , with the IC50 value of 49.4 uM. | |
| BCN5344 | Buddlejasaponin IV |
| 1. Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation, are responsible for the anti-inflammatory effects of buddlejasaponin IV. 2. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat. 3. Buddlejasaponin IV exerts antiinflammatory and cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes. 4. Buddlejasaponin IV may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. | |
| BCN5378 | Ophiopogonin B |
| 1. Ophiopogonin B is often used in Chinese traditional medicine to treat pulmonary disease, it is a prospective inhibitor of PI3K/Akt and may be used as an alternative compound to treat NSCLC. 2. Ophiopogonin B induces apoptosis, mitotic catastrophe and autophagy , has inhibitory effect on adhesion, invasion and migration of A549 cells in vitro. 3. Ophiopogonin B may be considered a potential inhibitor of gastric cancer progression, and may be used as an alternative compound for its treatment. | |
